B
Brian G. Monks
Researcher at University of Massachusetts Medical School
Publications - 42
Citations - 16808
Brian G. Monks is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Signal transduction & Inflammasome. The author has an hindex of 33, co-authored 41 publications receiving 14671 citations. Previous affiliations of Brian G. Monks include University of Bonn & Boston Medical Center.
Papers
More filters
Journal ArticleDOI
Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression.
Franz Bauernfeind,Gabor Horvath,Andrea Stutz,Emad S. Alnemri,Kelly S. MacDonald,David P. Speert,Teresa Fernandes-Alnemri,Jianghong Wu,Brian G. Monks,Katherine A. Fitzgerald,Veit Hornung,Eicke Latz +11 more
TL;DR: It is shown that cell priming through multiple signaling receptors induces NLRP3 expression, which is identified to be a critical checkpoint for NLRP2 activation and signals provided by NF-κB activators are necessary but not sufficient forNLRP3 activation.
Journal ArticleDOI
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta.
Annett Halle,Veit Hornung,Gabor C. Petzold,Cameron R. Stewart,Brian G. Monks,Thomas Reinheckel,Katherine A. Fitzgerald,Eicke Latz,Kathryn J. Moore,Douglas T. Golenbock +9 more
TL;DR: The NALP3 inflammasome is identified as a sensor of Aβ in a process involving the phagocytosis of A β and subsequent lysosomal damage and release of cathepsin B.
Journal ArticleDOI
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Rebecca C. Coll,Avril A. B. Robertson,Jae Jin Chae,Sarah C. Higgins,Raúl Muñoz-Planillo,Marco Inserra,Irina Vetter,Lara S. Dungan,Brian G. Monks,Andrea Stutz,Daniel E. Croker,Mark S. Butler,Moritz Haneklaus,Caroline E. Sutton,Gabriel Núñez,Eicke Latz,Daniel L. Kastner,Kingston H. G. Mills,Seth L. Masters,Kate Schroder,Mark E. Cooper,Luke A. J. O'Neill +21 more
TL;DR: MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle–Wells syndrome, and is a potential therapeutic for NLRP3-associated syndromes, and a tool for further study of theNLRP3 inflammasome in human health and disease.
Journal ArticleDOI
TLR9 signals after translocating from the ER to CpG DNA in the lysosome
Eicke Latz,Annett Schoenemeyer,Alberto Visintin,Katherine A. Fitzgerald,Brian G. Monks,Catherine F. Knetter,Catherine F. Knetter,Egil Lien,Nadra J. Nilsen,Terje Espevik,Douglas T. Golenbock +10 more
TL;DR: The data indicate a previously unknown mechanism of cellular activation involving the recruitment of TLR9 from the ER to sites of CpG DNA uptake, where signal transduction is initiated.
Journal ArticleDOI
LPS-TLR4 Signaling to IRF-3/7 and NF-κB Involves the Toll Adapters TRAM and TRIF
Katherine A. Fitzgerald,Daniel C. Rowe,Betsy J. Barnes,Daniel R. Caffrey,Alberto Visintin,Eicke Latz,Brian G. Monks,Paula M. Pitha,Douglas T. Golenbock +8 more
TL;DR: These studies suggest that TRIF and TRAM both function in LPS-TLR4 signaling to regulate the MyD88-independent pathway during the innate immune response to LPS.